Vera Therapeutics, Inc. $VERA Shares Bought by Armistice Capital LLC

Armistice Capital LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 22.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 653,796 shares of the company’s stock after acquiring an additional 117,796 shares during the quarter. Armistice Capital LLC owned 0.93% of Vera Therapeutics worth $33,108,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Vera Therapeutics during the 4th quarter worth $46,000. Quantbot Technologies LP bought a new position in Vera Therapeutics during the 2nd quarter worth $51,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Vera Therapeutics in the 4th quarter worth about $71,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Trading Up 4.0%

Shares of VERA stock opened at $35.01 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05. The stock has a fifty day moving average of $36.63 and a two-hundred day moving average of $41.52. The firm has a market capitalization of $2.51 billion, a PE ratio of -6.32 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the business posted ($0.81) earnings per share. As a group, research analysts expect that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 22,951 shares of the business’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the completion of the transaction, the chief executive officer owned 235,244 shares in the company, valued at approximately $10,362,498.20. The trade was a 8.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a report on Wednesday, March 11th. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. HC Wainwright increased their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $78.00.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.